You searched for "atrophy"
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
The natural history of treatment naïve choroidal neovascularisation (CNV) in geographic atrophy
The aim of this retrospective study is to assess the characteristics and natural history of quiescent CNV in geographic atrophy (GA) utilising multi-modal imaging. Case notes were reviewed of patients diagnosed with geographic atrophy between January 2010 and December 2016...
Anti-VEGF injections and macular atrophy progression in patients with nAMD in remission
This is a retrospective study of 59 eyes with neovascuar age-related macular degeneration (nAMD) with at least 6-month remission, to determine the effect of continuing anti-VEGF injections on the progression of macular atrophy (MA) during remission of nAMD. Group 1...Bosch-Boonstro-Schaaff optic atrophy syndrome (BBSOAS) NR2F1 mutation
An experienced ophthalmologist can make an anatomical diagnosis of childhood visual impairment based upon the surgical sieve, i.e., congenital and acquired. But an ophthalmologist cannot work in isolation to make an aetiological diagnosis – one would require the help of...Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...Hanson Wade: Dry AMD and Geographic Atrophy Therapeutics Summit 2025
Welcome to the 6th Dry AMD and Geographic Atrophy Therapeutics SummitTransformative Therapies for Dry, Intermediate & Late-Stage AMDWith late-phase trials advancing, novel mechanisms emerging, and global regulatory expectations evolving, the dry AMD and GA field is accelerating exponentially. Returning digitally...AI breakthrough brings geographic atrophy treatment a step closer
A team led by Dr Konstantinos Balaskas at Moorfields Eye Hospital Reading Centre has developed a fully automated, deep-learning model (algorithm) that can detect and quantify geographic atrophy using standard optical coherence tomography (OCT) scans.Cybersight: Using OCT as an Approach to Diagnose Glaucomatous and Other Optic Neuropathies
Clinically, the difference between glaucomatous and simple optic atrophy of other origins is not always clear. OCT with the ability to image and measure inner retinal layers in the macula and peripapillary area, with the measurement of rim atrophy, is...In conversation with Professor Usha Chakravarthy (2018)
Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...
